CLRB and CLRBZ Related Headlines
Go Back- Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
- Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
- Cellectar reports 12-month data for cancer drug in rare blood disorder
- Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
- Cellectar Biosciences raises up to $140 million in oversubscribed financing
- Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
- Cellectar enrolls first patient in breast cancer drug trial
- Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
CLRB and CLRBZ Related Press Releases
Go Back- Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
- Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
- Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
- Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
- Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
